Prenetics Global Ltd

Análisis de la acción Prenetics Global Ltd (PRE)

$18.520

+0.091 (+0.49%)Al cierre

Loading chart…
Máximo
18.870
Apertura
18.490
Precio medio ponderado por volumen
18.53
Volumen
118.10K
Capitalización
74.53M
Mínimo
18.190
Importe
2.19M
EV/EBITDA, TTM
-1.68

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

ir.prenetics.com

Análisis de IA of Prenetics Global Ltd (PRE)

Comprar

Prenetics Global Ltd is a good buy right now due to its current price of $17.35, which is well below the average analyst price target of $40. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue at $46.5 million, a 29% quarter-over-quarter increase. However, the main risk is the negative net income of -9 million in Q2 2026, which reflects ongoing losses despite revenue growth.

Métricas de valoración

El PER previsto actual de Prenetics Global Ltd (PRE) es 0.00, frente a su media de 5 años de -3.09.

PER previsto

Valor razonable
Media 5A P/E
-3.09
P/E actual
0.00
Sobrevalorada
2.54
Infravalorada
-8.71

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
4.88
EV/EBITDA actual
-1.68
Sobrevalorada
50.59
Infravalorada
-40.84

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.31
P/S actual
0.89
Sobrevalorada
2.13
Infravalorada
0.48

Escenarios de precio de Alphio AI para PRE

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%PRE

$19.74

Precio del escenario

B

Base

Base · 50%PRE

$16.65

Precio del escenario

B

Bajista

Bajista · 25%PRE

$14.46

Precio del escenario

Ballenas con PRE en cartera

A

Aspex Management (HK) Limited

+ Con en carteraPRE

-3.80%

Rentabilidad a 3 meses

Cronología de eventos

2026-07-14 (ET)

13:30:00

Prenetics Secures Around $1B Financing for IM8

2026-05-14 (ET)

09:10:00

IM8 Q1 Revenue Grows Nearly 6x Year-over-Year

09:10:00

IM8 Raises 2026 Revenue Guidance to $190M-$210M

2026-03-31 (ET)

09:30:00

Prenetics Files to Sell 2.36M Class A Ordinary Shares

2026-03-24 (ET)

11:10:00

Prenetics Global Partners with Superpower for Strategic Collaboration

Noticias

Preguntas frecuentes sobre PRE, respondidas por Alphio AI

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8. It operates in the Healthcare sector (ACCIDENT & HEALTH INSURANCE industry).

Prenetics Global Ltd is a good buy right now due to its current price of $17.35, which is well below the average analyst price target of $40. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue at $46.5 million, a 29% quarter-over-quarter increase. However, the main risk is the negative net income of -9 million in Q2 2026, which reflects ongoing losses despite revenue growth.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar